Login
$CNTX
$0.18 +$0.01 (5.61%) After hours

$CNTX 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Regulation FD Disclosure; Other Events

November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

05 Aug 2026 8-K: Regulation FD Disclosure

August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Co...

26 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Context Therapeutics Inc. (the “Company”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

15 Jun 2026 8-K: Regulation FD Disclosure; Other Events

June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

18 May 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corp...

01 May 2026 8-K: Other Events

As previously disclosed, on March 11, 2026, the Court of Chancery of the State of Delaware (the “Court”) approved a stipulation and proposed consent judgment (the “Stipulated Judgment”) regarding the stockholder class action complaint (t...

02 Apr 2026 8-K: Regulation FD Disclosure; Other Events

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

23 Mar 2026 8-K: Regulation FD Disclosure; Other Events

March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

13 Mar 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

CERTIFICATE OF CORRECTIONOFAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOFCONTEXT THERAPEUTICS INC.

27 Feb 2026 8-K: Other Events

On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court of Chancery of the State of Delaware (the “Court”) regarding the stockholder class action complaint (the “Action”) fil...

08 Jan 2026 8-K: Regulation FD Disclosure

January 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

05 Nov 2025 8-K: Regulation FD Disclosure; Other Events

November 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

24 Oct 2025 8-K: Entry into a Material Definitive Agreement; Other Events

This Amendment No. 1 (this “Amendment”) to the Sales Agreement, dated December 2, 2024 (the “Original Agreement”) is entered into as of the date first written above by Context Therapeutics Inc. (the “Company”) and Leerink Partners LLC (t...

20 Oct 2025 8-K: Other Events

As previously disclosed by Context Therapeutics Inc. (the “Company”) on that certain Current Report on Form 8-K filed on February 28, 2025 with the U.S. Securities and Exchange Commission (the “SEC”), on February 27, 2025, the Company re...

02 Sep 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar d...

12 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 12, 2025, Context Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2025, the record date for the Annual Meeting, there were 89,704,194 shares of common stock i...

02 Jun 2025 8-K: Regulation FD Disclosure; Other Events

June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

09 Apr 2025 8-K: Regulation FD Disclosure; Other Events

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody

28 Feb 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On February 27, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support